Traws Pharma Appoints Luba Greenwood to Its Board of Directors
Traws Pharma, Inc. has made a notable decision by welcoming Luba Greenwood as a new member of its Board of Directors. This addition comes as the company, which is focused on creating advanced therapies for respiratory viral diseases and cancer, continues its exciting journey of transformation and expansion. Greenwood’s vast experience in the life sciences field is expected to significantly enhance Traws Pharma’s goals and vision.
Farewell to James J. Marino
After ten years of dedicated service, James J. Marino, a valued member of the Board, will be stepping down. His departure signifies the end of a crucial chapter for Traws Pharma, where he played an essential role, including a four-year tenure as Chairman. The impact Marino made during his time on the Board has been considerable, and his expertise will certainly be missed as Traws Pharma embarks on its new phase.
Welcoming a Respected Leader
Iain Dukes, PhD, Executive Chairman of Traws, expressed his enthusiasm for Greenwood’s appointment. He highlighted her substantial background in the biopharmaceutical sector. Dukes pointed out that her previous roles as a board member for various public life science companies, combined with her time as Vice President of Global Business Development and M&A at Roche, make her exceptionally qualified to guide Traws through its upcoming developments.
Greenwood's Vision for Traws
Greenwood is equally excited about joining Traws Pharma at such a pivotal time. She emphasized the company’s strategic focus on expanding its product pipeline and noted the importance of its recent merger with Trawsfynydd, which represents a significant advancement for Traws Pharma’s goals. The integration of innovative technologies and scientific progress heralds a promising future for the company.
Paving the Path for Innovative Therapies
The progress being made in ongoing projects is impressive, particularly as Traws moves its respiratory antiviral therapies into Phase 1 studies while developing its oncology strategies. Greenwood is optimistic about these projects' advancement and is committed to creating significant value for both investors and stakeholders.
A Commitment to Innovation
Traws Pharma is dedicated to addressing unmet medical needs through innovative solutions. The company is currently focusing on two promising oral small molecule therapies in Phase 1 studies—tivoxavir marboxil for flu and ratutrelvir targeting COVID-19—positioning Traws for meaningful advancements. These therapies underscore Traws' commitment to leveraging cutting-edge drug development technologies to address major health challenges.
About Traws Pharma, Inc.
Traws Pharma is a clinical-stage biopharmaceutical company that specializes in developing oral small molecule therapies designed to combat respiratory viral diseases and different forms of cancer. With robust programs targeting both flu and COVID-19, along with an innovative oncology pipeline, Traws is at the forefront of biopharmaceutical innovation. The company's mission is clear: to enhance patient outcomes and reduce the burden posed by viral infections and cancer care.
Frequently Asked Questions
Who is Luba Greenwood?
Luba Greenwood is the newly appointed Director of Traws Pharma, with extensive experience in the life sciences and corporate governance sectors.
What prompted the change in Traws Pharma's Board?
The appointment of Greenwood, alongside Marino's departure, indicates a strategic shift focused on fortifying the company’s leadership and expanding growth opportunities.
What are Traws Pharma's main therapeutic focuses?
Traws Pharma primarily targets therapies for respiratory viral diseases and cancer, with promising developments in its product pipeline.
How is Traws Pharma advancing its projects?
The company is actively progressing its antiviral therapies into Phase 1 studies and advancing its oncology strategies, showcasing a proactive stance on drug development.
What does Traws Pharma aim to achieve?
Traws Pharma’s goal is to provide innovative solutions for significant medical challenges, specifically in the realms of viral infections and cancer treatment.
